pipette
ENEnglish

Scleral Allograft-Reinforced Cyclodialysis Combined with Phacoemulsification or Performed as a Standalone Procedure: 24-Month Outcomes from the Multicenter CREST Study

R. N. Weinreb, L. Provencher, A. S. Huang, A. Yadgarov, M. Rouse, B. Francis, T. Ianchulev, R. Chang

PreprintUso en el mundo real

En palabras de los autores

Introduction: Acellular scleral allograft-reinforced cyclodialysis is a bio-interventional surgery (BIOS) to lower intraocular pressure (IOP). We report 2-year efficacy and safety outcomes when the procedure is performed in combination with phacoemulsification and as a standalone procedure in eyes with open-angle glaucoma. Methods: Analysis of the multicenter CREST real-world evidence study of eyes undergoing allograft-reinforced cyclodialysis with AlloFlo Uveo (Iantrek, Inc., White Plains, NY; NCT05506423). Eyes attending the Month-24 visit were analyzed: 176 eyes undergoing phaco-combined surgery (Cohort 1) and 32 standalone eyes (Cohort 2). Values recorded after secondary procedures censored. Cohort 1 only was stratified by low, moderate, or high baseline IOP ([&le;] 15, 16-20, [&ge;] 21 mmHg). Results: A total of 176 eyes in Cohort 1 and 32 in Cohort 2 were analyzed. In Cohort 1, IOP decreased 3.1 mmHg at Month 24 from a baseline of 18.0 (-12.5%; p < 0.001), and medications decreased 0.5 from 1.5 (p < 0.001); medication-free eyes rose from 22.9% to 46.4% (p < 0.001). IOP changes in the low, moderate, and high baseline tiers were +0.9 (+7.8%), -3.0 (-16.3%), and -9.2 (-36.1%) mmHg; medication changes were -0.8, -0.6, and +0.1. In Cohort 2, IOP decreased 6.4 mmHg from 20.0 (-27.1%; p < 0.001), and medications decreased 1.2 from 2.8 (p = 0.004); medication-free eyes rose from 4.3% to 30.4% (p = 0.031). Secondary IOP-lowering procedures were performed in 5.1% of Cohort 1 eyes and 28.1% of Cohort 2. Kaplan-Meier freedom from reoperation was 98.9% and 84.4%. No eye developed clinically significant hypotony or choroidal effusion, and there were no allograft-related vision-threatening adverse events. Conclusion: Allograft-reinforced cyclodialysis effectively lowered IOP and medication use through 24 months.

Resultado principalEl resumen no menciona limitaciones.

Apareció: viernes, 6 de noviembre. medRxiv. Preprint, todavía sin revisión por pares.

DOI: 10.64898/2026.11.02.26367111